Comment on: A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis

被引：0
|
作者：
Sato, Takeo [1 ]
Inokuma, Shigeko [1 ]
机构：
[1] Japanese Red Cross Med Ctr, Dept Allerg Dis & Rheumatol, Shibuya Ku, Tokyo 1508935, Japan
来源：
RHEUMATOLOGY | 2010年 / 49卷 / 08期
关键词：
D O I：
10.1093/rheumatology/keq106
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1607 / 1607
页数：1
相关论文
共 50 条
  • [41] Mycophenolate mofetil in diffuse cutaneous systemic sclerosis: A registry-based retrospective analysis
    Nihtyanova, S. I.
    Black, C. M.
    Denton, C. P.
    RHEUMATOLOGY, 2006, 45 : I155 - I155
  • [42] Treatment with mycophenolate mofetil is associated with improved nailfold vasculature in systemic sclerosis
    Wildt, Marie
    Andreasson, Kristofer
    Hamberg, Viggo
    Hesselstrand, Roger
    Wuttge, Dirk M.
    RHEUMATOLOGY, 2024, 63 (02) : 385 - 391
  • [43] Importance of mycophenolate mofetil for treatment of interstitial lung disease in systemic sclerosis
    Schneider, Udo
    Siegert, Elise
    Glaser, Sven
    Kruger, Klaus
    Krause, Andreas
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2021, 80 (09): : 868 - 878
  • [44] Baricitinib for the treatment of cutaneous dermatomyositis: A prospective, open-label study
    Zhao, Qian
    Zhu, Zicong
    Fu, Qiaoyu
    Shih, Yanting
    Wu, Dan
    Chen, Lihong
    Zheng, Jie
    Cao, Hua
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (06) : 1374 - 1376
  • [45] Safety and tolerability of bosentan for digital ulcers in Japanese patients with systemic sclerosis: Prospective, multicenter, open-label study
    Hamaguchi, Yasuhito
    Sumida, Takayuki
    Kawaguchi, Yasushi
    Ihn, Hironobu
    Tanaka, Sumiaki
    Asano, Yoshihide
    Motegi, Sei-ichiro
    Kuwana, Masataka
    Endo, Hirahito
    Takehara, Kazuhiko
    JOURNAL OF DERMATOLOGY, 2017, 44 (01): : 13 - 17
  • [46] Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial
    Gaubitz, M
    Schorat, A
    Schotte, H
    Kern, P
    Domschke, W
    LUPUS, 1999, 8 (09) : 731 - 736
  • [47] Mycophenolate mofetil in the treatment of multiple sclerosis
    Pawate, Siddharama
    Wang, Lily
    Sriram, Subramaniam
    Moses, Harold
    NEUROLOGY, 2008, 70 (11) : A90 - A90
  • [48] SAFETY AND EFFICACY OF LENABASUM IN AN OPEN-LABEL EXTENSION OF A PHASE 2 STUDY IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS SUBJECTS (DCSSC)
    Spiera, Robert
    Hummers, Laura
    Chung, Lorinda
    Frech, Tracy
    Domsic, Robin
    Hsu, Vivian
    Furst, Daniel
    Gordon, Jessica
    Mayes, Maureen
    Simms, Robert
    Lee, Elizabeth
    Constantine, Scott
    Dgetluck, Nancy
    White, Barbara
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 245 - 245
  • [49] Efficacy and safety of oral cyclophosphamide versus mycophenolate mofetil in childhood nephrotic syndrome: an open-label comparative study
    Dhooria, Gurdeep Singh
    Bhargava, Siddharth
    Bhat, Deepak
    Pooni, Puneet Aulakh
    Goel, Nancy
    Kakkar, Shruti
    BMC NEPHROLOGY, 2024, 25 (01)
  • [50] Mitoxantrone in worsening secondary progressive multiple sclerosis: A prospective, open-label study
    Khatri, BO
    Wroblewski, M
    Kramer, J
    Dukic, M
    Poplar, A
    Anderson, AJ
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2006, 67 (01): : 55 - 65
12345